Global Retirement Partners LLC raised its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 101.5% during the first quarter, Holdings Channel reports. The firm owned 1,666 shares of the company’s stock after purchasing an additional 839 shares during the period. Global Retirement Partners LLC’s holdings in Aerie Pharmaceuticals were worth $30,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Aerie Pharmaceuticals during the 4th quarter valued at $3,310,000. Hsbc Holdings PLC increased its stake in Aerie Pharmaceuticals by 37.6% during the 4th quarter. Hsbc Holdings PLC now owns 22,407 shares of the company’s stock worth $302,000 after buying an additional 6,123 shares during the period. JPMorgan Chase & Co. increased its stake in Aerie Pharmaceuticals by 21.4% during the 4th quarter. JPMorgan Chase & Co. now owns 16,604 shares of the company’s stock worth $224,000 after buying an additional 2,928 shares during the period. Circle Wealth Management LLC increased its stake in Aerie Pharmaceuticals by 8.6% during the 4th quarter. Circle Wealth Management LLC now owns 19,240 shares of the company’s stock worth $260,000 after buying an additional 1,520 shares during the period. Finally, Truist Financial Corp increased its stake in Aerie Pharmaceuticals by 44.7% during the 4th quarter. Truist Financial Corp now owns 15,873 shares of the company’s stock worth $214,000 after buying an additional 4,902 shares during the period. Institutional investors own 99.89% of the company’s stock.
Shares of NASDAQ:AERI opened at $17.45 on Wednesday. The firm has a market cap of $818.70 million, a P/E ratio of -4.16 and a beta of 0.79. The company has a quick ratio of 3.10, a current ratio of 3.33 and a debt-to-equity ratio of 3.41. Aerie Pharmaceuticals, Inc. has a 12 month low of $9.01 and a 12 month high of $21.30. The company’s 50-day moving average price is $18.79 and its two-hundred day moving average price is $14.93.
Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, March 1st. Mizuho reaffirmed a “buy” rating and set a $28.00 price objective on shares of Aerie Pharmaceuticals in a report on Monday, December 28th. Finally, Needham & Company LLC assumed coverage on shares of Aerie Pharmaceuticals in a report on Friday, February 5th. They set a “buy” rating and a $26.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $22.70.
Aerie Pharmaceuticals Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.
Featured Story: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.